• CARsgen Presents CAR-Claudin18.2-T Data at 2018 CAR-TCR Summit pharmafocusasia
    September 10, 2018
    BOSTON, Sept. 8, 2018 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, presented its preliminary clinical data of a first-in-class CAR-Claudin18.2 T cell trial fo
PharmaSources Customer Service